What is Glaukos Corporation (GKOS) stock price?
Mar 28, 2022 · Glaukos' stock was trading at $38.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GKOS stock has increased by 65.0% and is now trading at $63.77. View which stocks have been most impacted by COVID-19.
Who are the top institutional investors buying GKOS stock?
Real time Glaukos (GKOS) stock price quote, stock graph, news & analysis.
What are the price targets for Glaukos'stock?
Dec 13, 2020 · A high-level overview of Glaukos Corporation (GKOS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Why should you hold Glaukos (GKOs) in your portfolio in 2021?
Is GKOS a good stock to buy?
The financial health and growth prospects of GKOS, demonstrate its potential to underperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.
Why is GKOS stock dropping?
What happened. Shares of Glaukos ( GKOS 2.10% ) were sinking 14.7% as of 3:28 p.m. EDT on Tuesday. The decline came after Wells Fargo analyst Larry Biegelsen downgraded the stock to an underweight rating from equal weight. Biegelsen also set a $41 price target for Glaukos, nearly 19% below its closing price on Monday.Jul 20, 2021
What does Glaukos company do?
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
Is Glaukos a buy right now?
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 1...
How has Glaukos' stock been impacted by Coronavirus (COVID-19)?
Glaukos' stock was trading at $38.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organiza...
When is Glaukos' next earnings date?
Glaukos is scheduled to release its next quarterly earnings announcement on Wednesday, May 4th 2022. View our earnings forecast for Glaukos .
How were Glaukos' earnings last quarter?
Glaukos Co. (NYSE:GKOS) released its quarterly earnings data on Monday, February, 21st. The medical instruments supplier reported ($0.31) earnings...
What guidance has Glaukos issued on next quarter's earnings?
Glaukos issued an update on its FY 2022 earnings guidance on Tuesday, March, 15th. The company provided earnings per share (EPS) guidance of for th...
What price target have analysts set for GKOS?
9 Wall Street analysts have issued 12 month price targets for Glaukos' stock. Their forecasts range from $34.00 to $105.00. On average, they antici...
Who are Glaukos' key executives?
Glaukos' management team includes the following people: Mr. Thomas William Burns , Chairman, CEO & Pres (Age 61, Pay $1.14M) Mr. Joseph E. Gilli...
What is Thomas W. Burns' approval rating as Glaukos' CEO?
10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com . Thomas W. Burns has an approval rating of 100% among Glaukos' employees. Th...
Who are some of Glaukos' key competitors?
Some companies that are related to Glaukos include NovoCure (NVCR) , Penumbra (PEN) , Tandem Diabetes Care (TNDM) , Globus Medical (GMED) , In...
About Glaukos
Glaukos (NYSE:GKOS) Frequently Asked Questions
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.
What is Glaukos Corporation?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Glaukos stock.
Where is Glaukos located?
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
